Journal articles are published in English.
Oncopept has moved a patient-specific tumour-to-peptide workflow into clinical use in Russia. Explore how the platform works, the research supporting it and the cohort evidence that can define its precision-oncology potential.
On 31 March 2026, a patient with colorectal cancer reportedly received Russia’s personalised peptide therapeutic vaccine Oncopept. By the public announcement on 14 April, the patient had received three doses with good tolerability. This was a meaningful manufacturing and clinical milestone: a complete tumour-to-vaccine workflow had moved into clinical use for one person.
Oncopept matters because it treats peptides as programmable, patient-specific information. Tumour sequencing identifies molecular targets, computational analysis helps select matching neoantigens, and a bespoke set of peptides is manufactured to focus an immune response. The platform brings genomics, peptide synthesis, quality control and clinical immunology into one precision-oncology pathway. Our introduction to what peptides are explains why their ordered amino-acid sequences can carry such specific biological instructions.
Russia’s Federal Medical-Biological Agency told GxP News that Oncopept was first administered on 31 March 2026 and that a vaccine had already been prepared for a second participant. Russian authorities had reportedly authorised clinical use for colorectal cancer in November 2025. The programme details show both the scale of interest and the precision required for a medicine made separately for every patient.
Three well-tolerated doses in one person provide an encouraging first tolerability observation. Peer-reviewed Oncopept cohort outcomes remained the next publication milestone at the time of review, giving the programme a clear opportunity to add tumour-response, recurrence, survival and immune-response data to this first-use record.
Cancer cells accumulate mutations. Some alter proteins and create abnormal fragments called neoantigens, which can act as molecular flags on a tumour cell while being absent from healthy tissue. A personalised vaccine begins by comparing tumour material with a normal reference sample and identifying the mutations most likely to produce useful targets for that patient’s HLA type.
Several targets may be included because tumours are genetically diverse and can change under pressure. Prediction quality therefore matters at every step. The most useful sequence set is one that can be manufactured consistently and produces measurable immune recognition in the individual patient.
Most colorectal cancers are microsatellite stable (MSS), a biology that generally produces fewer obvious immune signals and responds less often to checkpoint-inhibitor immunotherapy than mismatch-repair-deficient disease. A personalised neoantigen strategy aims to select the most relevant molecular flags from the individual tumour instead of relying on one universal antigen.
Early research provides a reason for optimism. In a preliminary study of six patients with recurrent or metastatic MSS colorectal cancer, personalised neoantigen vaccination produced detectable neoantigen-specific immune responses in four patients. Other peptide-vaccine studies in colorectal and pancreatic cancer have also shown that vaccine-induced T-cell responses and molecular biomarker changes are biologically possible.
The public record reviewed for this article establishes entry into clinical use, three doses with good tolerability in one person, preparation of a second personalised batch and operation of a broader selection programme. Cohort reporting can progressively add the outcomes that matter most for understanding the platform’s clinical profile.
Longer-term research can also identify which patients benefit most, whether vaccination is particularly useful after surgery when tumour burden is low, and how combinations with checkpoint inhibitors, chemotherapy or other immune therapies influence the response. Each answer would strengthen the wider case for personalised peptide manufacturing in precision oncology.
Oncopept shows that future value can sit in the complete system around a peptide: tumour sampling, data quality, target selection, synthesis, analytical testing, stability, documentation, logistics and clinical follow-up. Forty-nine days is already a notable turnaround for a bespoke medicine, and continued workflow development can make personalised manufacturing more responsive and scalable.
For clinics, laboratories and professional partners, the practical lesson is the importance of documented identity, reproducible manufacture, traceable quality control and precise communication about the evidence stage. Labbieux applies the same product-specific mindset across its documented products and professional partner pathway.
Oncopept is a personalised peptide therapeutic vaccine reported by Russia’s Federal Medical-Biological Agency for clinical use in colorectal cancer. Each patient’s tumour data guides the selection of a bespoke peptide sequence set intended to focus an immune response on tumour-specific targets.
Yes. The first reported patient received an initial dose on 31 March 2026 and had received three doses with good tolerability by the 14 April announcement. This first-use milestone opens the way for cohort-level reporting to define immune responses and clinical outcomes.
The peptide set is selected from mutations identified in an individual patient’s tumour. The manufacturing platform and quality process can stay consistent, while the biological instructions in the final sequence set are tailored to that patient’s molecular profile.
The next evidence phase can report participant characteristics, selected peptide targets, immune responses, imaging, circulating tumour DNA, recurrence, survival and longer-term tolerability. Together, those measures can define where the platform offers the greatest clinical value.
Oncopept has moved a complex patient-specific workflow from design into clinical use. Its integration of tumour genomics, computational selection, peptide manufacture and immune monitoring gives precision oncology a distinctive platform whose potential can now be defined through transparent cohort evidence.
Epitalon grew out of five decades of pineal-peptide research, while the defined AEDG tetrapeptide has a more recent history. Trace its origin, first verifiable dates, landmark findings and the questions shaping its clinical potential.
Peptides are biological messages: short amino-acid chains that can tell cells when to release hormones, manage energy, respond to injury and rebuild tissue. Here is why peptide science is reshaping medicine, aesthetics and human performance.